Medicare Drug Price Negotiations Yield $12 Billion Savings on 15 Key Medications
New Medicare drug price negotiations under the Inflation Reduction Act cut costs for 15 major medications, saving Medicare $12 billion annually.
U.S. Healthcare and Insurance Outlook for 2026: AI, Policy, and Market Trends
Comprehensive 2026 outlook on U.S. healthcare and insurance sector covering AI adoption, Medicare Advantage growth, pharmaceutical scrutiny, market consolidations, and emerging health equity focus.
Medicare Drug Price Negotiations Cut Costs for 15 Key Medications
New Medicare drug price negotiations reduce government costs on 15 high-spend medications, including cancer and diabetes treatments, saving $12 billion annually.
Trump Administration Secures Medicare Drug Price Cuts for 15 Medications
The Trump administration finalizes agreements reducing Medicare prices for 15 drugs, aiming to save billions and impact Medicare Part D plans and drug affordability policies.
Pharma Firms Slash Medicare Drug Prices in Trump Administration Deal
Pharmaceutical companies agree to significant Medicare drug price cuts under Trump administration, projecting billions in savings with impacts on Medicare Part D and drug affordability.
CMS Launches Voluntary Medicaid MFN Drug Pricing Model; Trump-Era Manufacturer Agreements Expand
CMS unveils the GENERous Medicaid payment model introducing MFN drug pricing, alongside expanded Trump administration drug pricing agreements and key regulatory updates for 2026.
Novo Nordisk, Eli Lilly Cut GLP-1 Prices for Expanded Medicare Market Access
Novo Nordisk and Eli Lilly agree to lower GLP-1 drug prices in exchange for expanded Medicare and Medicaid coverage, marking a major shift in U.S. drug pricing and access.
Impact of MFN Drug Pricing Policy on Medicare Part D Deadline Approaches
The looming deadline for drugmakers to comply with the Most Favored Nation drug pricing policy raises concerns over potential disruptions to Medicare Part D, highlighting regulatory and market risks for U.S. drug pricing and federal entitlement programs.
GLP-1 Drugs Pose Coverage Challenges Amid Proven Health Benefits
Analysis finds GLP-1 drugs like semaglutide offer real health benefits but raise insurance coverage and cost challenges amid growing demand in the U.S. market.
FTC Warns Healthcare Employers on Noncompetes; Industry Sees Rising Unionization and Tech Advances
FTC cautions healthcare employers on noncompetes. Rising physician unionization, Medicare Plan Finder updates, Kaiser-Renown joint venture, AI tools, FDA drug approvals, and robotic intubation device mark key healthcare industry trends in 2025.